CDK12 and Familial prostate cancer: The extent to which CDK12 loss confers sensitivity to single-agent PARP inhibition remains contentious; in prostate cancer, the tandem duplication resulting from biallelic CDK12 loss results in increased neoantigen generation and enhanced sensitivity to immunotherapy59.